Please select the option that best describes you:
Topics:
Thoracic Malignancies • Medical Oncology
How would approach post chemoradiation consolidation in a patient with stage III lung adenocarcinoma with an EGFR exon 18 G719A mutation and highly positive PDL1 level?
These mutations were not eligible in Laura trial. Afatinib has a more durable PFS than osimertinib in these patients.
How would you chose between durvalumab, osimertinib, and afatinib?